About US
Contact us
-
Lallemand inaugurates its newest division - “Lallemand Health Solutions”Montreal, Canada... Lallemand Inc is pleased to announce the birth of its new division ‘’Lallemand Health Solutions’’. This new entity consolidates the internationally recognized probiotic manufacture2013/2/6
-
While BMS shops emerging markets brands, GSK wraps $900M buy in IndiaTwo consumer health deals, two Big Pharma approaches toward emerging markets. While Bristol-Myers Squibb ($BMY) is looking around for buyers for a portfolio of consumer brands in Latin America, GlaxoS2013/2/6
-
SFDA issues notice on implementation of electronic supervision of imported drugsTo implement the 2011-2015 Work Plan for Electronic Supervision of Drugs and other related work requirements, the State Food and Drug Administration (SFDA) recently issued a notice on implementation o2013/2/5
-
FDA approves generic Doxil to combat drug shortageIt can pay to play with the FDA when it needs help with drug shortages. In a push to ease a months-long shortage of Johnson & Johnson's($JNJ)cancer drugDoxil, the FDA fast-tracked a generic fromSu2013/2/5
-
Exports to U.S. to power Indian drugmaker growthThe market forIndiandrugmakers is looking good. Growth this year could reach 20% as exports to the U.S. are driving sales, a report from India Ratings says. "Of the export markets, Indian pharma will2013/2/4
-
U.S. finally gets payment rule publishedIt is 15 months overdue and it will be more than a year before information is public, but at last the government has set out its rule for how it will publishpaymentsfrom drugmakers to doctors. Drug a2013/2/4
-
Merck has to trim outlook as pipeline poops outMerckCEOKenneth Fraziertoday had to give shareholders the bad news and then he had to follow that up with the really bad news. Profit fell 7.3% in the fourth quarter as generics ate the lunch of its2013/2/1
-
OTC plant bites Novartis' reputation againThe closed Novartis ($NVS) consumer products plant in Lincoln, NE, that has besmirched the drug giant's reputation and frustratedCEO Joseph Jimenezhas bitten the company again. This time Novartis ack2013/2/1
-
Sanofi nabs FDA approval for Kynamro, despite safety concernsThe FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY)Genzymeunit. But the agency's blessing came with some strings attached: Four post2013/1/31
-
EU enforcers accuse J&J, Novartis of delaying fentanyl genericJohnson & Johnson ($JNJ) and Novartis ($NVS) are the latest pharma companies to feel the ire of EU antitrust regulators.European Commissionofficials have accused the two drugmakers of delaying a g2013/1/31